RE: Sierra quarterly reports4 Mar 2023 14:30
The absract below taken from Journal of Thoracic Oncology. Authors Trperna Sen and John V Heymach to name just two. Mid 2019. John V Heymach is also an advisor to GSK.
'Next, we expanded our study to an immunocompetent SCLC model to explore both the intrinsic and immune-mediated antitumor effects of the SRA737 + LDG regimen in combination with anti–PD-L1. We first determined that SCLC cell lines H209, H524, and RPP were resistant to monotherapy gemcitabine in vitro (Supplementary Fig. 3B), with the RPP tumor model described above selected for further in vivo testing. RPP tumor bearing B6129F1 immunocompetent mice were treated with LDG (40 mg/kg, 1/7, first day of week), SRA737 (100 mg/kg, 2/7 first and second days of week), and anti–PD-L1 (300 µg, 1/7, third day of week) as single agents or in combination.
The SRA737 + LDG regimen mimicked the schedule currently being used in the clinical trial described above with or without anti–PD-L1 on the third day of a weekly cycle. We did not observe a significant antitumor effect with any single-agent treatments (anti–PD-L1, SRA737, or LDG), and only a moderately delayed tumor growth with combined SRA737 and PD-L1 treatment (Fig. 4A).
However, we observed remarkable tumor regressions when we combined SRA737 + LDG with anti–PD-L1. All mice achieved some level of tumor regressions and 8 of 10 (80%) mice had complete tumor regressions which were sustained up to 60 days post treatment (Fig. 4A).
NOTE THE ABOVE SMALL CELL LUNG CANCER ( already developed resistance to Gemcitabine)
GSK would be aware of this.
Forward just over 2 years
Confirmed objective response rate was 46% in patients treated with investigational dostarlimab combination versus 37% in the pembrolizumab combination
THE ABOVE IS NON SMALL CELL LUNG CANCER that has received no previous treatment.
Yes and before you say SRA737 is preclinical in vivo ( mice) and GSK is in human I am aware
Sign In
Follow the stocks
